ScholarX: KIM, BYOUNG GIE

Detailed Information

KIM, BYOUNG GIE (김병기)

Medicine (Medicine)

Research Area

Tel 02-3410-3513
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Prognosis:23||Laparoscopy:19||Uterine cervical neoplasms:17||Survival:15||Recurrence:14||Cervical cancer:14||cervical cancer:13||Ovarian cancer:9||Ovarian Neoplasms:9||Ovarian neoplasms:9||Chemotherapy:8||Gynecology:8||Epithelial ovarian cancer:8||prognosis:8||Endometrial cancer:8||Hysterectomy:7||immunohistochemistry:6||Adenocarcinoma:6||Surgery:5||Borderline ovarian tumors:5||survival:4||Ovarian neoplasm:4||laparoscopy:4||Immunotherapy:4||Cisplatin:4||Ovary:4||ovarian neoplasms:4||Bevacizumab:4||Endometrial Neoplasms:4||Singleport:4||Ovarian carcinoma:4||Prognostic factor:4||Magnetic resonance imaging:4||Borderline ovarian tumor:4||HPV:3||Pembrolizumab:3||Adjuvant radiotherapy:3||LESS:3||Epithelial Ovarian Cancer:3||Laparoscopic surgery:3||Pregnancy:3||Clear cell carcinoma:3||Uterine Cervical Neoplasms:3||lymph node:3||magnetic resonance imaging:3||Neoplasm staging:3||ovarian cancer:3||Concurrent chemoradiation:3||Lymph nodes:3||One port:3||Radiotherapy:3||Lymphatic metastasis:3||Early cervical cancer:3||cervical intraepithelial neoplasia:3||cervix neoplasms:3||CA125:3||siRNA:3||Immunohistochemistry:3||surgery:3||targeted therapy:3||endometrial cancer:3||epithelial ovarian cancer:3||Endometrial neoplasms:3||MicroRNA:3||uterine cervical neoplasms:3||Stage:3||Minimally invasive surgery:3||overall survival:2||Radiation:2||p53:2||advanced ovarian cancer:2||Lymph Node Excision:2||Histology:2||Olaparib:2||Dynamin 2:2||Cervical Cancer:2||Choriocarcinoma:2||Operative outcome:2||Carcinoma:2||Conization:2||Adjuvant chemoradiotherapy:2||Optimal cytoreduction:2||Molecular target:2||Uterine cervical cancer:2||Outcome:2||Ovarian Cancer:2||metastasis:2||Human papillomavirus:2||DNA ploidy:2||Lynch syndrome:2||Prognostic factors:2||lymphadenectomy:2||carcinoma:2||BRCA1:2||Tumor marker:2||uterus:2||Laparotomy:2||Retrospective studies:2||Biomarker:2||Tremelimumab:2||Risk factor:2||Elderly:2||Paclitaxel:2||Risk factors:2||radical hysterectomy:2||recurrence:2||laparotomy:2||cisplatin:2||Myoma:2||Robotics:2||Topotecan:2||Carboplatin:2||Ifosfamide:2||Galectin1:2||Geriatric Assessment:2||Ovarian tumor:2||complication:2||Endometrial Cancer:2||concurrent chemoradiation:2||concurrent chemoradiotherapy:2||HER2:2||Bartholin glands:2||consolidation chemotherapy:2||Overall survival:2||Korean Gynecologic Oncology Group:2||sphingosine kinase 1:2||Laparoscopic myomectomy:2||squamous cell:2||PAUF:2||diseasefree survival:2||Single port:2||Single port access:2||Adjuvant chemotherapy:2||Single port access (SPA):2||Poly(ADPribose) Polymerase Inhibitors:2||Cytoreductive surgery:2||hysterectomy:2||Uterine fibroid:2||Uterine leiomyoma:2||HPV 16:2||Neoplasm metastasis:2||neoadjuvant chemotherapy:2||Uterus:2||HPV 18:2||Propensity ScoreMatching:2||Singleport access:2||Leiomyoma:2||Benign metastasizing leiomyoma:2||Colorectal cancer:2||microarray:2||therapeutic vaccine:2||Mesothelial cell:2||Uterine cervical neoplasm:2||Cervical intraepithelial neoplasia:2||ovary:2||Drug therapy:2||Lung:2||Durvalumab:2||adenoid cystic carcinoma:2||Galectin3:1||Galectin7:1||Gene expression signature:1||Gene regulation:1||Genetic profiling:1||Genetictesting:1||Genexol:1||GenexolPM:1||Genomewide association study:1||Geriatric:1||Gestational trophoblastic disease:1||Gliomatosis peritonei:1||Glucose:1||Grade 3 endometr:1||Gynecologic laparoscopy:1||Gynecologic malignancy:1||Gynecological surgery:1||HE4:1||HER3:1||HIF2α:1||HIFU:1||HPV genotyping:1||HPV infection:1||Haematological problems:1||Hemoglobins:1||Hereditary:1||High tesla magnetic resonance imaging:1||Highgrade serous carcinoma:1||Highintensity focused ultrasound ablation:1||Homologous recombination repair:1||Hormone therapy:1||Human Papillomavirus:1||Human genome:1||Human papillomavirus (HPV):1||Humanized:1||Hypoxia:1||ID2:1||Image analysis:1||Imageguided brachytherapy:1||Immune checkpoint inhibitor:1||Immunotherapy Recurrence:1||In vivo:1||Incidence:1||Inclusion:1||Indocyanine green:1||International Federation of Gynecology and Obstetrics:1||Intraoperative Complications:1||Intraoperative tumor rupture:1||Intraperitoneal bupivacaine:1||Invasion:1||Invasive implant:1||Keywords: FertilitySparing Surgery:1||Korea:1||Koreans:1||LGESS:1||La:1||Laminin:1||Laparoendoscopic singlesite surgery (LESS):1||Laparoscopicassisted vaginal hysterectomy:1||Laparoscopicassisted vaginal hysterectomy (LAVH):1||Laparoscopically assisted vaginal hysterectomy:1||Late complications:1||Learning curve:1||Leiomyosarcoma:1||Length of stay:1||Less invasive surgery:1||Local:1||Locally advanced cervical carcinoma:1||Longterm survival:1||Losartan:1||Low anterior resection:1||Low malignant:1||Lymph:1||Lymph node:1||Lymph node excision:1||Lymphadenectomy:1||Lymphangitis carcinomatosa:1||Lymphocytes:1||Lymphovascular space invasion:1||MRI:1||Machine Learning:1||Maintenance:1||Maintenance Therapy:1||Maintenance therapy:1||Malignant fibrous histiocytoma:1||Malignant germ cell tumor:1||MatchedPair Analysis:1||Matchedcase comparison:1||Melanoma:1||Mesenchymal tumor:1||Metabolic syndrome:1||Metastasectomy:1||Metastatic carcinoma:1||Metastatic tumors to the ovary:1||MiR200 family:1||MiTMAB:1||MicroRNA200c:1||Microarray:1||Microenvironment:1||Microinvasive carcinoma:1||Minimally invasive surgical procedure:1||Mitotic count:1||Modifiable factors:1||Modified suture technique:1||Molecular Targeted Therapy:1||Molecular ta:1||Molecular targeted therapy:1||Monoclonal:1||Monocyte:1||Monocytes:1||Mortality:1||Mucinous cystadenoma:1||Mucinous tumors:1||Multivariate analysis:1||Myomectomy:1||Myxoid:1||Myxoma:1||Neoadjuvant Chemotherapy:1||Neoadjuvant chemotherapy:1||Neoadjuvant therapy:1||Neoplasm invasiveness:1||Neoplasm recurrence:1||Neuroendocrine tumor:1||Neutrophils:1||New classification:1||Niraparib:1||Nomograms:1||Nondiabetic:1||Nongestational:1||Normalsized Ovarian Carcinoma:1||Nuclear staining:1||OcTMAB:1||OctoPort:1||Omeprazole:1||Oncology:1||Operative time:1||Optimal cyt:1||Optimal debulking surgery:1||Ovarian Epithelial:1||Ovarian Epithelial Cancer:1||Ovarian blood supply:1||Ovarian epithelial cancer:1||Ovarian function:1||Ovarian metastasis:1||Ovarian metastatectomy:1||Ovarian neoplas:1||Ovarian reserve:1||Ovarian serous carci:1||Ovarian teratoma:1||Ovarian transposition:1||Ovariancancer:1||PARP inhibitor:1||PARPinhibitors:1||PET:1||PET/CT:1||PNA:1||PNA microarray:1||POM121:1||Pain:1||Papillomavirus vaccines:1||Paraaortic lymphadenectomy:1||Parametrial involvement:1||Parametrium:1||Pathology:1||Pathology Section:1||Patientderived xenograft:1||Patientderived xenograft model:1||Pazopanib:1||Peritoneal tuberculosis:1||Perivascular epithelioid cell tumor (PEComa):1||Persistent infection:1||Pharmacogenomic analysis:1||Phase II trial:1||Placental site trophoblastic tumor:1||Platinum Resistant:1||Platinumfree interval:1||Platinumresistant ovarian cancer:1||Population attributable fraction:1||Port site metastasis:1||Postoperative computed tomography:1||Practice Pattern:1||Precision medicine:1||Preservation:1||Preterm birth:1||Primary peritoneal cancer:1||Primary repair:1||Prognostic model:1||Progression free survival:1||Progression to invasive carcinoma:1||Progressionfree survival:1||Propensity Score:1||Proportional hazards models:1||Protein array analysis:1||Proton pump inhibitors:1||Pulmonary lymphangitic carcinomatosis:1||Pulmonary recruitment maneuver:1||Quality of life questionnaire:1||RARβ:1||RNAseq:1||ROMA:1||RPPA:1||Radiation therapy:1||Radical Hysterectomy:1||Radical Trachele:1||Radical hysterectomy:1||Radical surgery:1||Radical trachelectomy:1||Radioresistance:1||Ramosetron:1||Rare Diseases:1||Rectal:1||Recurrenc:1||Recurrent epithelial ovarian cancer:1||Reproductive factors:1||Resection margin:1||Residual tumor:1||Resistance:1||Response rate:1||Retinoic acid receptors:1||Retreatment:1||Retroperitoneal space:1||Retrospective Studies:1||Revised FIGO staging:1||Risk factor for recurrence:1||Robotic surgery:1||Roboticassisted laparoscopic surgery:1||Sphase:1||SPA:1||SUVmax:1||Safety:1||Salpingoovariectomy:1||Salvage Therapy:1||Satisfaction:1||Secondary cytoreductive surgery:1||Sensitivity:1||Serous cystadenoma:1||Sexuality and Gynecologic Cancer:1||Shoulder pain:1||Singleport access (SPA):1||Singleport access (SPA) surgery:1||Singleport myomectomy:1||Singlesite robotic surgery:1||Sirolimus:1||Small interfering RNA:1||Sodium selenite:1||Sorafenib:1||South Korea:1||Squamous cell carcinom:1||Squamous cell carcinoma:1||Squamous cell carcinomarelated antigen:1||Squamous cell lesions:1||Stage I endometrial cancer:1||Staging operation:1||Subrenal capsule implantation:1||Subtotal hysterectomy:1||Surgical Instruments:1||Survival Rate:1||Survival analysis:1||Survival benefit:1||Survival rate:1||Synchronous gynecologic tumor:1||TCGA:1||THZ1:1||TIP (paclitaxel, ifosfamide, cisplatin):1||TP53 mutations:1||Tetraarsenic hexoxide:1||Therapeutic target:1||Time management:1||Tolllike receptor 5:1||Toxicity:1||Treatment:1||Treatment interval:1||Tumor growth:1||Tumor invasion:1||Uterine Neoplasms:1||Uterine artery ligation:1||Uterine carcinoma:1||Uterine carcinosarcoma:1||Uterine carcinosarcomas:1||Uterine cervix:1||Uterine neoplasm:1||Uterine papillary serous carcinomas:1||VATPase:1||VAS score:1||Vaccine:1||Vacuolar protontranslocating ATPases:1||Variant of unknown significance:1||Villoglandular adenocarcinoma:1||Vincristine:1||Vulva:1||Vulvar cancer:1||Waiting time:1||Yeast twohybrid analysis:1||aCGH:1||adjuvant treatment:1||adverse effects:1||age:1||ancestry:1||animal model:1||ascites:1||baseline lymphocyte count:1||belotecan:1||benign metastasizing leiomyoma:1||biomarker:1||biomarkers:1||body image:1||borderline ovarian tumor:1||borderline ovarian tumour:1||brain metastases:1||breast neoplasms:1||bulky cervical cancer:1||bulky cervical carcinoma:1||calpain 6:1||calpain 6 protein:1||cancer antigen 125 (CA 125):1||carboplatin:1||carcinosarcoma:1||case:1||cervical carcinoma:1||cervical neoplasia:1||cervical ripening:1||cervical squamous cell carcinoma:1||chemoradioresistance:1||chemotherapy:1||clear cell adenocarcinoma:1||clear cell carcinoma:1||clearcell carcinoma:1||clinical trial:1||clinical trials, phase II as topic:1||co:1||colposcopy:1||combination:1||computed tomographic scan:1||conization:1||contr:1||cosmesis:1||cystectomy:1||cytoreductive surgery:1||domainII:1||domainT:1||dualmodality imaging:1||dynamic contrastenhanced magnetic resonance imaging:1||dynamin 2:1||eQTL:1||endocytosis:1||endometriosis:1||epidemiology:1||expression microarray:1||fertilitysparing surgery:1||followup studies:1||fourfactor model:1||galectin3:1||gammaknife radiosurgery:1||gene expression profiling:1||gene signature:1||genes:1||germline mutation:1||gynandroblastoma:1||gynecologic cancer:1||gynecology:1||highdoserate brachytherapy:1||highintensity focused ultrasound:1||histologic subtype:1||histology:1||homologous recombination repair mutation:1||hormone replacement therapy:1||hormone therapy:1||human:1||human epidermal growth factor receptor:1||human papillomavirus:1||immune checkpoint inhibitor:1||immune checkpoint inhibitors:1||immunotherapy:1||inclusion:1||intermediaterisk group:1||juvenile granulosa cell tumor:1||laparoendoscop:1||laparoendoscopic singlesite:1||laparoscopic single site surgery:1||laparoscopically assisted vaginal hysterectomy:1||large ovarian tumor:1||leiomyoma:1||locally advanced cervical cancer:1||locally advanced cervical carcinoma:1||longterm followup:1||loss of heterozygosity:1||lymph nodes:1||mTOR:1||maintenance therapy:1||matrix metalloproteinase2:1||mature cystic teratoma:1||metastatic carcinoma:1||miR155:1||minimallyinvasive surgery:1||misoprostol:1||mitomycinC:1||monocyte:1||multitRNA synthetase complex:1||myoma:1||neoplasm invasiveness:1||neoplasms:1||nodule:1||olaparib:1||olaparibbased combination:1||optimal debulking:1||oral:1||outcome:1||ovarian neoplasm:1||ovarian ser:1||ovary MRI:1||ovary PET:1||ovary neoplasm:1||ovary of normal size:1||pSTAT3:1||paclitaxel:1||pads:1||pap smear:1||papillary serous carcinoma:1||papillomavirus:1||paraaortic lymph node:1||pathology:1||patient care bundles:1||patientderived xenograft:1||pelvic insufficiency fracture:1||pelvic radiotherapy:1||perioperative care:1||peripheral tolerance:1||platinum:1||platinumresistant:1||platinumresistant recurrent ovarian cancer:1||pmTOR:1||polyADP ribose polymerase inhibitor:1||postmenopausal woman:1||postoperative complications:1||prediction:1||prediction of optimal cytoreduction:1||pregnancy:1||primary peritoneal carcinoma:1||programmed cell death 1 receptor:1||progression:1||promoter hypermethylation:1||propensity score matching:1||protein expression:1||protocolKoEVE study:1||pseudomyxoma peritonei:1||pure groundglass:1||quantitative trait loci:1||recurrent cervical carcinoma:1||recurrent epithelial ovarian cancer:1||recurrent ovarian epithelial carcinoma:1||recurrent ovarian tumor:1||regression:1||regulatory T cells:1||resectability:1||residual:1||retroperitoneal space:1||risk factor:1||risk factors:1||s gland:1||screening low dose CT:1||selfantigen:1||selfexamination:1||single port access:1||singlenucleotide polymorphism:1||singleport access:1||splicing var:1||squamous cell carcinoma:1||squamous epithelium:1||stage IB1:1||sublingual:1||surgical staging:1||the 2001 Bethesda System:1||therapeutic target:1||tolllike receptor:1||toxicity:1||trastuzumab:1||treatment:1||treatment efficacy:1||treatment outcome:1||tumor regression:1||tumor suppressor genes:1||umbrella study:1||unilateral salpingooophorectomy:1||universal grade:1||uterine cancers:1||uterine cervical neoplasm:1||vaccine:1||vaginal:1||vincristine:1||vulvar cancer:1||.:1||vulvar carcinoma:1||67kDa laminin receptor:1||9vHPV:1||AGR2:1||AGTR1:1||AIMP2:1||ASCH:1||ASCUS:1||Ablation therapy:1||Accuracy:1||Adenocarcinoma in situ:1||Adenoid cystic carcinoma:1||Adjuvant Chemotherapy:1||Adjuvant Therapy:1||Adjuvant therapy:1||Adnexal surgery:1||Advanced ovarian cancer:1||Advancedstage:1||Adverse effects:1||Aged:1||Anemia:1||Aneuploidy:1||Annexin A4:1||AntiMullerian hormone:1||Antibodies:1||Antineoplastic agents:1||Appendectomy:1||Appendix:1||Aprepitant:1||Ascites:1||Asia:1||Asian:1||Asian ancestry:1||Asian women:1||Atypical carcinoid:1||Atypical glandular cells:1||Atypical squamous cells:1||Autophagy:1||B cell:1||BR:1||BRCA1 gene:1||BRCA1 genes:1||BRCA2 gene:1||BRCA2 gene mutation:1||BRCA2 genes:1||BRCAmutations:1||BRD7:1||BSO:1||BVACC:1||Barbed suture:1||Bartholin&apos:1||Benign adnexal mass:1||Benign ovarian tu:1||Beta blocker:1||Biological markers:1||Biomechanics:1||Bladder dissection technique:1||Bone metastasis:1||Borderline tumor:1||Breast cancer:1||Breast neoplasms:1||Bulky earlystage cervical cancer:1||CA 125:1||CA125 Antigen:1||CA125:1||CA199:1||CAIX:1||CD24:1||CD8(+) T cell:1||CTR1:1||CTR2:1||Calpain 6 protein:1||Cancer:1||Carbohydrate Antigen 125:1||Carcinoid:1||Carcinoma in situ:1||Casecontrol study:1||Cell death:1||Cell survival:1||Cervical Invasion:1||Cervical carcinoma:1||Cervical carcinoma cell:1||Cervical cerclage:1||Cervical neoplasm:1||Cervical neoplasms:1||Cervix:1||Cervix uteri:1||Cesarean section:1||Chemoradiotherapy:1||Chemoradiation:1||Chemoradiotherapy:1||Chemosensitivity:1||ClavienDind:1||Clear Cell Carcinoma:1||Clear cell:1||Cluster analysis:1||Cold coagulation:1||Colon:1||Complication:1||Concurrent chemoradiotherapy:1||Conservative surgery:1||Consolidation chemotherapy:1||Conventional:1||Cosmetic:1||Costeffectiveness · Human papillomavirus 16/18 genotyping · Cervical cancer screening.:1||Costutility:1||Cyclindependent kinase 7:1||Cystectomy:1||Cytoreduction surgical procedures:1||DASL assay:1||DD6:1||DNA vaccine:1||Dacarbazine:1||Data Collection:1||Decidual reaction:1||Dexamethasone:1||Diagnosis:1||Diagnostic Techniques and Procedures:1||Diagnostic imaging:1||Disease free survival:1||Double primary cancers:1||Drug Therapy, Combination:1||Drug resistance:1||Dynasore:1||E:1||ENOTES:1||ERCC1:1||Electrosurgical conization:1||Endocervix:1||Endometrial ca:1||Endometrial carcinoma:1||Endometrial stromal sarcoma:1||Endometrioid Carcinoma:1||Endometrioid carcinoma:1||Endometriosis:1||Endometrium:1||Enhanced recovery after surgery (ERAS):1||Enhancer:1||Epidemiology:1||Epithelial endometrial carcinomas:1||Epithelial ovarian tumors:1||Esomeprazole:1||Etoposide:1||European Organization for Research and Treatment of Cancer QLQCX24:1||FIGO:1||FIGO stage:1||FIGO staging:1||FSH:1||FTY720:1||Fertility:1||Fertility Preservation:1||Fertility sparing:1||Fertilitysparing surgery:1||Fibroblast growth factor receptor:1||Flow cytometry:1||Fluorescence:1||Fluorodeoxyglucose F18:1||Frozen section:1||GOG criteria:1||

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE